January 31, 2023 02:40 PM ESTUpdated February 1, 04:53 AM
People
FDA+

Amid ap­pli­ca­tion tsuna­mi, FDA's top cell and gene ther­a­py leader to re­tire in March

Zachary Brennan

Senior Editor

The FDA is in a bind and what it needs most right now is the ex­per­tise nec­es­sary to vet a mas­sive pipeline of cell and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

TRENDING NOW

New fund will pres­sure flail­ing biotechs, as in­vestor frus­tra­tion boils over

FDA chief Makary talks ex­pe­dit­ing drug ap­provals, RIFs and the abor­tion pill

Ake­so shares new da­ta sug­gest­ing it can beat Keytru­da on sur­vival, wins Chi­na ap­proval

Paul Stof­fels on re­tir­ing from Gala­pa­gos; Boehringer In­gel­heim switch­es up lead­er­ship

J&J re­ports dura­bil­i­ty da­ta for blad­der can­cer 'pret­zel' drug af­ter FDA fil­ing

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times